API
Choline Fenofibrate
KDMF APIs
Choline Fenofibrate
Korean name | 페노피브레이트콜린 |
|---|---|
Category | Central nervous system |
CAS No. | 856676-23-8 |
KDMF registration No. | 20180814-209-J-48(3) |
Manufacturer | Alembic Pharmaceuticals Limited(API Unit-1) |
Specification | In-house |
Product information
Synonyms | Fenofibric acid choline salt |
|---|---|
Description | Fenofibrate is a third generation fibric acid derivative that is predominantly administered as monotherapy to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B and alternatively to increase high-density lipoprotein cholesterol in patients diagnosed with primary hyperlipidemia or mixed dyslipidemia and to reduce triglycerides in patients with severe hypertriglyceridemia. Fenofibrate however is generally extremely lipophilic, largely insoluble in water, and poorly absorbed 1 . As the primary active metabolite of fenofibrate however, various hydrophilic salt formulations of fenofibric acid have since been developed, resulting in therapeutic agents that demonstrate far greater solubility, absorption throughout the gastrointestinal tract, bioavailability, and capability to be administered irrespective of patient food intake |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)